Schott Pharma AG KGaAFRA:1SX -0.98%67 Net Margin % is 12.51% as of Mar. 2026, which is 19% below its 10-year median of 15.40. GuruFocus rates FRA:1SX with a GF Score™ of 67/100 and a GF Value™ of €6.49. The stock has 2 warning signs investors should review. Among 818 Medical Devices & Instruments companies, Schott Pharma AG KGaA ranks better than 81.91% on this metric.
The historical rank and industry rank for Schott Pharma AG KGaA's Net Margin % or its related term are showing as below:
FRA:1SX'
s Net Margin % Range Over the Past 10 Years
Min: 13.26 Med: 15.4 Max: 16.9
Current: 14.45
FRA:1SX's Net Margin % is ranked better than 81.91% of 818
companies
in the Medical Devices & Instruments industry
Industry Median: 2.06
vs FRA:1SX: 14.45
Schott Pharma AG KGaA (FRA:1SX) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Schott Pharma AG KGaA Net Margin % Related Terms
Schott Pharma AG KGaA Net Margin % Historical Data
* Premium members only.
The historical data trend for Schott Pharma AG KGaA's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1SX vs ISRG, BDX, MDLN: Net Margin % Comparison
For the Medical Instruments & Supplies subindustry, Schott Pharma AG KGaA's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Schott Pharma AG KGaA Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Schott Pharma AG KGaA's Net Margin % distribution charts can be found below:
* The bar in red indicates where Schott Pharma AG KGaA's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Schott Pharma AG KGaA (FRA:1SX) has a Net Margin % of 12.51% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Schott Pharma AG KGaA and its competitors. This is 19% below median its historical median of 15.40. Over the past decade, Schott Pharma AG KGaA's Net Margin % has ranged from 13.26 to 16.90. According to the industry distribution chart, Schott Pharma AG KGaA ranks #148 out of 818 companies in the Medical Devices & Instruments industry, placing it in the top 18.1%.
Is Schott Pharma AG KGaA's Net Margin % too high?
Schott Pharma AG KGaA's current Net Margin % of 12.51% is 19% below median its 10-year median of 15.40. Over the past 10 years, this metric has ranged from a low of 13.26 to a high of 16.90. The Medical Devices & Instruments industry median Net Margin % is 2.06. Schott Pharma AG KGaA's value of 12.51% is 507.3% above this industry median. Based on the distribution chart, Schott Pharma AG KGaA ranks #148 out of 818 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Schott Pharma AG KGaA has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Schott Pharma AG KGaA's Net Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Schott Pharma AG KGaA ranks #148 out of 818 companies for Net Margin %. This places Schott Pharma AG KGaA in the top 18% of its industry — outperforming the majority of peers. The industry median Net Margin % is 2.06. Schott Pharma AG KGaA's value of 12.51% is 507.3% above this benchmark. Historically, Schott Pharma AG KGaA's own Net Margin % has ranged from 13.26 to 16.90 over the past decade. While the company's 10-year median is 15.40 vs. the industry median of 2.06, Schott Pharma AG KGaA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.06, based on 818 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Schott Pharma AG KGaA's current Net Margin % of 12.51% is 507.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Schott Pharma AG KGaA and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Schott Pharma AG KGaA's current Net Margin % is 12.51%, which is 19% below median its own 10-year median of 15.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Schott Pharma AG KGaA stock overvalued right now?
Schott Pharma AG KGaA (FRA:1SX) has a current Net Margin % of 12.51%. The stock's GF Value™ is €6.49, compared to a current price of €4.04 — trading 37.8% below its estimated fair value. The current Net Margin % is 12.51%, which is 19% below median its 10-year median of 15.40 and 507.3% above the Medical Devices & Instruments industry median of 2.06. Schott Pharma AG KGaA's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Schott Pharma AG KGaA (FRA:1SX), the current Net Margin % is 12.51% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Schott Pharma AG KGaA (FRA:1SX) Overvalued in 2026?
Based on GuruFocus' analysis, Schott Pharma AG KGaA stock appears to be undervalued.
The current stock price of €4.04 is trading 37.8% below its estimated GF Value™ of €6.49.
Key valuation signals for FRA:1SX:
Net Margin %: 12.51% (19% below median its 10-year median of 15.40)
GF Value™: €6.49 vs. price of €4.04 (37.8% below fair value)
Industry Position: 507.3% above the Medical Devices & Instruments median (#148 of 818)
No single metric tells the full story. See the FRA:1SX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Schott Pharma AG & CO KGaA is an international provider of drug containment solutions and delivery systems for injectable drugs for pharma, biotech and life-sciences. Its business operates in two segments: Drug Containment Solutions (DCS) and Drug Delivery Systems (DDS). The majority of revenue is being generated from the DCS segment, which includes products like vials, cartridges, and ampoules, and provides customers with sterile and non-sterile options in standard and high-end formats for drug storage. Geographically, the company generates revenue from Europe, the Middle East, Africa (EMEA), Asia and the South Pacific, North America, and South America.
67GF Score
Get the complete analysis for FRA:1SX
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1SX has been successfully added to your 
